Review of mass spectrometry-based metabolomics in cancer research.

Review of mass spectrometry-based metabolomics in cancer research.
复制标题

DOI:
10.1158/1055-9965.epi-13-0584
复制
发表时间:
2013-12
期刊:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子:
--
通讯作者:
Ulrich CM
Ulrich CM
中科院分区:
其他
文献类型:
--
作者:
Liesenfeld DB;Habermann N;Owen RW;Scalbert A;Ulrich CM

文献摘要

被引文献

相似文献

代谢组学是对生物系统中存在的所有代谢物的系统研究,用于许多人类疾病(包括癌症)的生物标志物开发。在这篇综述中,我们调查目前的作用,质谱代谢组学为基础的癌症研究。在PubMed、Embase和Web of Knowledge数据库中进行了文献综述。我们纳入了106项研究,报告了7种不同样本类型中的21种不同类型的癌症。代谢组学在癌症研究中最常用于病例对照比较。次要应用包括翻译领域,如患者预后、治疗控制和肿瘤分类或分级。代谢组学在流行病学方面处于发展阶段,大多数研究包括<100例患者。特别是在样品制备和数据分析方面需要标准化。在这篇综述的第二部分,我们通过定量提取所有关于代谢物改变的报告,重建了癌症患者的代谢网络:能量代谢、膜和脂肪酸合成的改变出现了,色氨酸水平在各种癌症中变化最频繁。代谢组学有可能发展成为流行病学和转化癌症研究中未来应用的标准工具,但还需要进一步的大规模研究,包括前瞻性验证。
Metabolomics, the systematic investigation of all metabolites present within a biological system, is used in biomarker development for many human diseases, including cancer. In this review we investigate the current role of mass spectrometry-based metabolomics in cancer research. A literature review was carried out within the databases PubMed, Embase and Web of Knowledge. We included 106 studies reporting on 21 different types of cancer in 7 different sample types. Metabolomics in cancer research is most often used for case-control comparisons. Secondary applications include translational areas, such as patient prognosis, therapy control and tumor classification or grading. Metabolomics is at a developmental stage with respect to epidemiology, with the majority of studies including <100 patients. Standardization is required especially concerning sample preparation and data analysis. In a second part of this review, we reconstructed a metabolic network of cancer patients by quantitatively extracting all reports of altered metabolites: Alterations in energy metabolism, membrane and fatty acid synthesis emerged, with tryptophan levels changed most frequently in various cancers. Metabolomics has the potential to evolve into a standard tool for future applications in epidemiology and translational cancer research, but further, large-scale studies including prospective validation are needed.